Cargando…
Neurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction
Melatonin is a highly pleiotropic signaling molecule, which is released as a hormone of the pineal gland predominantly during night. Melatonin secretion decreases during aging. Reduced melatonin levels are also observed in various diseases, such as types of dementia, some mood disorders, severe pain...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific World Journal
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354573/ https://www.ncbi.nlm.nih.gov/pubmed/22629173 http://dx.doi.org/10.1100/2012/640389 |
_version_ | 1782233246216486912 |
---|---|
author | Hardeland, Rüdiger |
author_facet | Hardeland, Rüdiger |
author_sort | Hardeland, Rüdiger |
collection | PubMed |
description | Melatonin is a highly pleiotropic signaling molecule, which is released as a hormone of the pineal gland predominantly during night. Melatonin secretion decreases during aging. Reduced melatonin levels are also observed in various diseases, such as types of dementia, some mood disorders, severe pain, cancer, and diabetes type 2. Melatonin dysfunction is frequently related to deviations in amplitudes, phasing, and coupling of circadian rhythms. Gene polymorphisms of melatonin receptors and circadian oscillator proteins bear risks for several of the diseases mentioned. A common symptom of insufficient melatonin signaling is sleep disturbances. It is necessary to distinguish between symptoms that are curable by short melatonergic actions and others that require extended actions during night. Melatonin immediate release is already effective, at moderate doses, for reducing difficulties of falling asleep or improving symptoms associated with poorly coupled circadian rhythms, including seasonal affective and bipolar disorders. For purposes of a replacement therapy based on longer-lasting melatonergic actions, melatonin prolonged release and synthetic agonists have been developed. Therapies with melatonin or synthetic melatonergic drugs have to consider that these agents do not only act on the SCN, but also on numerous organs and cells in which melatonin receptors are also expressed. |
format | Online Article Text |
id | pubmed-3354573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | The Scientific World Journal |
record_format | MEDLINE/PubMed |
spelling | pubmed-33545732012-05-24 Neurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction Hardeland, Rüdiger ScientificWorldJournal Review Article Melatonin is a highly pleiotropic signaling molecule, which is released as a hormone of the pineal gland predominantly during night. Melatonin secretion decreases during aging. Reduced melatonin levels are also observed in various diseases, such as types of dementia, some mood disorders, severe pain, cancer, and diabetes type 2. Melatonin dysfunction is frequently related to deviations in amplitudes, phasing, and coupling of circadian rhythms. Gene polymorphisms of melatonin receptors and circadian oscillator proteins bear risks for several of the diseases mentioned. A common symptom of insufficient melatonin signaling is sleep disturbances. It is necessary to distinguish between symptoms that are curable by short melatonergic actions and others that require extended actions during night. Melatonin immediate release is already effective, at moderate doses, for reducing difficulties of falling asleep or improving symptoms associated with poorly coupled circadian rhythms, including seasonal affective and bipolar disorders. For purposes of a replacement therapy based on longer-lasting melatonergic actions, melatonin prolonged release and synthetic agonists have been developed. Therapies with melatonin or synthetic melatonergic drugs have to consider that these agents do not only act on the SCN, but also on numerous organs and cells in which melatonin receptors are also expressed. The Scientific World Journal 2012-05-02 /pmc/articles/PMC3354573/ /pubmed/22629173 http://dx.doi.org/10.1100/2012/640389 Text en Copyright © 2012 Rüdiger Hardeland. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Hardeland, Rüdiger Neurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction |
title | Neurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction |
title_full | Neurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction |
title_fullStr | Neurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction |
title_full_unstemmed | Neurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction |
title_short | Neurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction |
title_sort | neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354573/ https://www.ncbi.nlm.nih.gov/pubmed/22629173 http://dx.doi.org/10.1100/2012/640389 |
work_keys_str_mv | AT hardelandrudiger neurobiologypathophysiologyandtreatmentofmelatonindeficiencyanddysfunction |